Management of Hyperkalemia in Post-Bypass Patients

Immediate Management Steps

For a patient with a high potassium level, the American Heart Association recommends discontinuing eplerenone immediately as potassium >6.0 mEq/L is considered severe hyperkalemia and requires prompt intervention 1, 2
Obtain an ECG to assess for hyperkalemia-related changes, such as peaked T waves, flattened P waves, prolonged PR interval, and widened QRS, as recommended by the American College of Cardiology 1
Consider hospital admission for monitoring and treatment if ECG changes are present or the patient is symptomatic, according to the American Heart Association 1
Recheck potassium and renal function within 24-48 hours, as suggested by the American Heart Association 3, 4
Assess for other contributing factors to hyperkalemia, including medication review, dietary potassium intake, renal function, and volume status, as recommended by the American College of Cardiology 2, 3, 4, 5

The American College of Cardiology states that potassium >6.0 mEq/L represents severe hyperkalemia with increased risk of cardiac arrhythmias and sudden death 1
Guidelines recommend discontinuation of aldosterone antagonists when potassium exceeds 5.5 mEq/L, according to the American Heart Association 5, 6, 4

Recheck potassium and renal function within 24-48 hours after discontinuing eplerenone, as recommended by the American Heart Association 3, 2
Continue monitoring potassium levels at least weekly until stabilized below 5.5 mEq/L, according to the American College of Cardiology 2
Counsel the patient to avoid high-potassium foods and supplements, as suggested by the American Heart Association 5, 2

When restarting eplerenone, use a lower dose (12.5 mg daily or every other day), as recommended by the American College of Cardiology 3, 2
Monitor potassium within 3-7 days after restarting, according to the American Heart Association 2

Failing to discontinue eplerenone with severe hyperkalemia (>6.0 mEq/L), as warned by the American College of Cardiology 1
Inadequate follow-up monitoring after medication changes, according to the American Heart Association 2
Restarting eplerenone too soon or at too high a dose, as cautioned by the American College of Cardiology 3, 4
Not considering other contributing factors to hyperkalemia, such as medication review, dietary potassium intake, renal function, and volume status, as recommended by the American Heart Association 5, 4
Not instructing patients to temporarily stop eplerenone during episodes of dehydration, diarrhea, or when loop diuretic therapy is interrupted, as suggested by the American College of Cardiology 5, 7